|
| |
| | [No title] |
 | | Quantitatively it is the most important of the two pathways, but is slower to cleave fibrin than the extrinsic pathway. | | | The intrinsic pathway ultimately activates factor X, a process which can also be brought about by the extrinsic pathway. | | | There is evidence that the Hageman factor can autoactivate, thus the pathway is self-amplifying. |
|
http://www.fantalizee.com/article.aspx?articleid=100096
|
|
| |
| | Activated Partial Thromboplastin Time |
| | Factor deficiencies that prolong PTT: The PTT is more sensitive to deficiencies of the intrinsic pathway (factors VIII, IX, XI, XII, prekallikrein, HMWK) than it is to deficiencies of the common pathway (fibrinogen, and factors II, V, and X). | | | The PTT is more sensitive to intrinsic pathway factor deficiencies than to common pathway factor deficiencies. | | | Therefore, in these situations, an alternative assay, such as the Heparin Antifactor Xa Assay, should be used rather than the PTT to monitor heparin. |
|
http://www.mgh.harvard.edu/labmed/lab/coag/handbook/co003400.htm
|
|
| |
| | Biomaterials 18 (1997) 1511-1522 |
| | Both the contact phase and the common pathway were subjected to a detailed theoretical analysis to establish the effect of mass transport and flow, surface reactivity, feedback loops and other parameters of interest in the cascades. | | | The common pathway is so effective at producing thrombin that it does not take much to set it off. | | | It is only under these flow conditions that we can argue that activated clotting factors are washed downstream or diluted by the rapidly flowing blood before they can build up to significant concentration - the conventional explanation for distinguishing high flow, white thrombus formation from low flow, red thrombus formation. |
|
http://www.elsevier.com/homepage/sai/biomaterials/181511/181511.htm
|
|
| |
| | APS & FXII |
| | Therefore the need for additional management should be assessed according to the presence of concurrent risk factors in an algorithmic fashion.8 Since his cranial nerve palsy resolved quickly and there was no family history of vascular thrombosis he was treated empirically with aspirin, although there is no evidence to support its benefit in this condition. | | | Revaluation of the incidence of thromboembolic complications in congenital Factor XII deficiency—a study on 73 subjects from 14 Swiss families. | | | Antibodies to FXII found in 50% of patients with APS |
|
http://www.microedgedata.co.uk/aps/aps_fxii_4.htm
|
|
| |
| | Oestrogenic repression of human coagulation factor VII expression mediated through an oestrogen response element ... |
| | Results are shown for the two common polymorphic haplotypes (h1 and h2) in each of the three constructs, for the promotorless parent construct pGL3 Basic (pGL3B) and also for the construct pGL3-FXII. | | | Promoter activities are expressed relative to the activity of the corresponding construct in the absence of oestrogenic factors. | | | 52 The Writing Group for the Estradiol Clotting Factors Study (1996) Effects on haemostasis of hormone replacement therapy with transdermal estradiol and oral sequential medroxyprogesterone acetate: a 1-year, double-blind, placebo-controlled study. |
|
http://hmg.oupjournals.org/cgi/content/full/11/7/723
|
|
| |
| | New Page 1 |
| | · Factor Xa forms the crossroads of the two clotting systems by participating in both the extrinsic and the intrinsic pathways. | | | Platelet activation I ntrinsic Pathway Extrinsic Pathway Tissue factor Pathway | | | It is however, important clinically, for it forms the basis of initiating the APTT and can give test results that may confuse some clinicians. |
|
http://www.reddymed.com/hdbc/pathwayintrinsic.htm
|
|
| |
| | Citysearch Attorneys |
| | Just do a search in Google (http://www.google.com) for “Factor XII Deficiency pharmacy” (or drugs or medicine) and you’ll find one that has what you are looking for. | | | Need drugs, a pharmacy, or medicine for Factor XII Deficiency? | | | Or, perhaps you are looking for a Factor XII Deficiency treatment or an alternative cure? You can find people through Google that offer these services as well. |
|
http://www.stilltheking.com/resources2742.htm
|
|
| |
| | DiaPharma Support FAQ Protein S-Free |
| | Activation of FXII occurs following administration of clot-busting drugs like tPA, which is also likely to contribute to the activation of the complement and kinin systems that has been demonstrated following thrombolytic therapy. | | | Increased thrombin generation in patients given thrombolytic therapy is partially mediated through an increased activation of factor XII to AFT. | | | This is partly due to factor XII deficiency not being associated with any overt clinical symptoms. |
|
http://www.diapharma.com/faq/diapharma_faq_aft.htm
|
|
| |
| | Binding of activated Factor XII to endothelial cells affects its inactivation by the C1-esterase inhibitor -- Schousboe ... |
| | Palmer, R.M.J., Ferrige, A.G. and Moncada, S. (1987) Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. | | | Hence, the function of FXII may be localized | | | Silverberg, M., Dunn, J.T., Garen, L. and Kaplan, A.P. (1980) Autoactivation of human Hageman factor. |
|
http://www.ejbiochem.org/cgi/content/full/270/1/111
|
|
| |
| | Dr. Koop - Factor XII Deficiency- Health Encyclopedia and Reference |
| | To find more information on specific conditions, please visit our partner sites: | | | Deficiency of factor XII is considered a rare clotting disorder, and it involves no clinical bleeding. | | | Koop - Factor XII Deficiency- Health Encyclopedia and Reference |
|
http://www.drkoop.com/encyclopedia/93/674.html
|
|
| |
| | Energy Citations Database (ECD) - Energy and Energy-Related Bibliographic Citations |
| | 550201 -- Biochemistry-- Tracer Techniques; BLOOD COAGULATION FACTORS-- BIOLOGICAL EFFECTS;GROWTH FACTORS-- AMINO ACID SEQUENCE; DNA SEQUENCING;DOSE-RESPONSE RELATIONSHIPS;HEPATOMAS;LEUCINE;MITOGENS;PURIFICATION;THYMIDINE;TRITIUM COMPOUNDS;TUMOR CELLS | | | Availability information may be found in the Availability, Publisher, Research Organization, Resource Relation and/or Author (affiliation information) fields and/or via the "Full-text Availability" link. | | | For a journal article, please see the Resource Relation field. |
|
http://www.osti.gov/energycitations/product.biblio.jsp?osti_id=5933984
|
|
| |
| | Factor XII |
| | The use of Thrombelastography to study possible disturbances of the fibrinolytic mechanism in patients with the antiphospholipid syndrome. | | | The antiphospholipid syndrome is a complex heterogeneous clinical condition where the presence of antiphospholipid antibodies is associated with venous or arterial thrombosis and/or recurrent fetal loss. | | | The structure and function of factor XII and the antiphospholipid syndrome |
|
http://www.kent.ac.uk/bio/jones/Research
|
|
| |
| | Bleeding Disorders |
| | Inherited factor VII deficiency is a chronic, life-long disorder. | | | A deficiency in any of these factors can lead to bleeding problems, each with its own symptoms and treatments. | | | For example, some people with low levels of factor VII do not have bleeding problems. |
|
http://www.accredohealth.net/hhs/bleeding_disorders/other.html
|
|
| |
| | factor XII deficiency - General Practice Notebook |
| | The information provided herein should not be used for diagnosis or treatment of any medical condition. | | | Hageman's disease is a rare disorder characterised by deficiency of Hageman factor (Factor XII). | | | Oxbridge Solutions Ltd® is an independent company owned by the authors which does not receive income from any other organisation or individual. |
|
http://www.gpnotebook.co.uk/cache/-959447013.htm
|
|
| |
| | [No title] |
| | There are usually no symptoms associated with this deficiency, but there may be symptoms of mild blood loss in some cases. | | | This is an inherited disorder; there is no known way to prevent it. | | | HAGEMAN FACTOR DEFICIENCY - A deficiency of a specific blood clotting factor (XII) that may be genetic or acquired. |
|
http://www.icomm.ca/geneinfo/hfd.htm
|
|
| |
| | NHF Bleeding Disorders Information Center Factor XII Deficiency |
| | It is an autosomal recessive disorder, which means if the clotting defect is inherited from a parent, the child will be a genetic carrier of the condition, but may or may not have symptoms. | | | There are usually no symptoms for factor XII deficiency. | | | However, it's been suggested that factor XII deficiency may predispose to thrombosis. |
|
http://www.hemophilia.org/bdi/bdi_types10.htm
|
|
| |
| | Factor XII - Wikipedia, the free encyclopedia |
| | It may increase the risk of thrombosis, due to inadequate activation of the fibrinolytic pathway. | | | Deficiency does not cause excessive haemorrhage as the other coagulation factors make up for the it. | | | Hageman factor was first discovered in 1955 when a routine preoperative blood sample of the 37-year-old railroad brakeman John Hageman was found to have prolonged clotting time in test tubes, even though he had no haemorrhagic symptoms. |
|
http://en.wikipedia.org/wiki/Hageman_factor
|
|
| |
| | Factor XII Activity |
| | A number of investigators have reported that congenital factor XII deficiency may be associated with an increased incidence of venous thrombosis. | | | In fact, mild factor XII deficiency is the most common cause of extended aPTT in the non-bleeding patient in the absence of lupus anticoagulant. | | | Decreased factor XII levels can be seen in liver disease and renal disease. |
|
http://www.labcorp.com/datasets/labcorp/html/chapter/mono/cf001200.htm
|
|
| |
| | Factor XII assay (Test) - Southwest Washington Medical Center |
| | Veins and arteries vary in size from one patient to another and from one side of the body to the other. | | | Factor XII deficiency is not normally associated with clinical bleeding and Factor XII does not appear to be necessary for the formation of clots for normal hemostasis (stopping of bleeding). | | | This is a blood test to measure the activity of factor XII -- one of the substances involved in coagulation (blood clotting). |
|
http://www.swmedicalcenter.com/11374.cfm
|
|
| |
| | Haematologic Technologies - Factor XII |
| | Reciprical activation of XII to the active serine protease factor XIIa (XIIa) by kallikrein is central to initiation of the intrinsic coagulation pathway. | | | The ability of a variety of negatively charged substances, both physiological and nonphysiological to promote XII activation and, thus, initiation of the intrinsic pathway has led to the psuedonym "contact activation". | | | Zymogen; precursor to the serine protease factor XIIa; activated by kallikrein/HMWK/anionic surface complex to intitiate the intrinsic pathway |
|
http://www.haemtech.com/Zymogens/Factor_XII.htm
|
|
| |
| | Hageman Factor Deficiency - Quest Diagnostics Patient Health Library |
| | This disorder is thought to be benign and usually presents no symptoms (asymptomatic); it is usually only accidentally discovered through pre-operative blood tests that are required by hospitals. | | | Although it is thought that Factor XII is needed for blood clotting, when it is deficient, other blood clotting factors tend to compensate for its absence. | | | Hageman Factor Deficiency - Quest Diagnostics Patient Health Library |
|
http://www.questdiagnostics.com/kbase/nord/nord499.htm
|
|
| |
| | factor xii from On-line Medical Dictionary |
| | Deficiency of factor xii, also called the hageman trait, leads to increased incidence of thromboembolic disease. | | | Along with prekallikrein, it serves as the contact factor that initiates the intrinsic pathway of blood coagulation. | | | Published at the Centre for Cancer Education, University of Newcastle upon Tyne |
|
http://cancerweb.ncl.ac.uk/cgi-bin/omd?factor+xii
|
|
| |
| | Factor XII Activity Assay |
| | Factor XII deficiency accounts for many instances of prolonged activated partial thromboplastin time assays but has no clinical consequence, even in pregnancy or surgery. | | | Congenital factor XII deficiency is present in 1-3 % of individuals and is inherited as an autosomal recessive mutation. |
|
http://peir.path.uab.edu/coag/article_69.shtml
|
|
| |
| | Factor XII |
| | Antibodies to FXII were found to occur in approximately 50% of patients with the antiphospholipid syndrome (APS). | | | Jones DW, Gallimore MJ, Mackie IJ, Harris SL, Winter M. (2000) Reduced factor XII levels in patients with the antiphospholipid syndrome are associated with antibodies to factor XII. | | | Jones DW, Mackie IJ, Gallimore MJ, and Winter M. (2001) Antibodies to factor XII and recurrent fetal loss in patients with the antiphospholipid syndrome. |
|
http://www.kent.ac.uk/bio/jones/Research/pr.htm?file=antibodies.htm
|
|
| |
| | C1-Esterase Inhibitor: An Anti-Inflammatory Agent and Its Potential Use in the Treatment of Diseases Other Than ... |
| | C1-Inh is the only known inhibitor of C1s and C1r of the classical pathway of the complement system, as well as a major inhibitor of FXIIa and kallikrein of the contact system and of FXIa, which links the contact activation system to the coagulation cascade. | | | C1-Inh is the only known inhibitor of the activated serine proteinases C1s and C1r from the classical pathway of complement, | | | factors such as FXII and prekallikrein by bacterial lipopolysaccharides |
|
http://pharmrev.aspetjournals.org/cgi/content/full/52/1/91
|
|
| |
| | Factor XII assay - A Medical Reference Article |
| | Factor XII assay - A Medical Reference Article | | | A resource with information on over 10,000 medical topics including: Factor XII assay |
|
http://www.marylandophthalmology.com/dwp/002626.htm
|
|
| |
| | Factor XII Deficiency - Hageman Trait - information page with HONselect |
| | It normally occurs in the absence of patient or family history of hemorrhagic disorders and is marked by prolonged clotting time. | | | Synonym(s): Hageman Trait / Deficiency, Factor XII / Deficiencies, Factor XII / Factor XII Deficiencies / | | | Definition: An absence or reduced level of blood coagulation factor XII. |
|
http://www.hon.ch/HONselect/RareDiseases/EN/C15.378.100.141.330.html
|
|
| |
| | Activation of the kallikrein-kinin system by cardiopulmonary bypass in humans -- Campbell et al. 281 (4): 1059 -- AJP - ... |
| | Licker, M, Neidhart P, Lustenberger S, Valloton MB, Kalonji T, Fathi M, and Morel DR. Long-term angiotensin-converting enzyme inhibitor treatment attenuates adrenergic responsiveness without altering hemodynamic control in patients undergoing cardiac surgery. | | | Human plasma prekallikrein (Fletcher factor) clotting activity and antigen in health and disease. | | | Plasma kallikrein/kinin system: a revised hypothesis for its activation and its physiologic contributions. |
|
http://ajpregu.physiology.org/cgi/content/full/281/4/R1059
|
|
| |
| | factor xii assay from On-line Medical Dictionary |
| | Low factor XII may be seen in cases of congenital deficiency of factor XII, heparin administration and liver disease. | | | A test used to measure the activity of a blood clotting factor XII. | | | Published at the Centre for Cancer Education, University of Newcastle upon Tyne |
|
http://cancerweb.ncl.ac.uk/cgi-bin/omd?factor+xii+assay
|
|
| |
| | Hemic and Lymphatic Diseases |
| | Guidelines on Therapeutic products to treat haemophilia and other hereditary coagulation disorders - UK Haemophilia Centre, Oxford | | | Activated Protein C Resistance: The Most Common Risk Factor for Venous Thromboembolism [A DR Sheppard] - FamilyPractice.Com | | | Factor V Leiden Mutation and the Risks for Thromboembophilic Disease: A Clinical Perspective [Price and Ridker] - Ann Int Med '97 |
|
http://www.mic.ki.se/Diseases/C15.html
|
|
| |
| | Abstract number: OC2400 |
| | Increasing knowledge of the interaction between the contact activation system and the endothelial cells has suggested that the vascular wall is the physiological site of activation of this system as well as the reactions derived from this. | | | I factor XII exhibited the same Zn optimum (15 µM) as the binding of purified factor XII/factor XIIa suggesting that a local increase of Zn is the triggering factor for the binding and the reactions followed as a consequence of this binding to endothelial cells in the vascular wall. | | | In this context the binding and activation of HK with kallikrein has been thoroughly investigated while binding of factor XII to endothelial cells has been analysed only superficially. |
|
http://www.schattauer.de/abstracts/absOC2400.html
|
|
| |
| | QED Coagulation Factor Monoclonal Antibodies Antibody |
| | Several different monoclonal antibodies to human coagulation factors are available from QED. | | | Murine MAb recognizes the light chain of human Factor XII. | | | Murine MAb recognizes the light chain of human high molecular weight kininogen. |
|
http://www.qedbio.com/coagulation.htm
|
|
| |
| | Factor XII Light Chain Antibody Search - Biocompare |
| | You may broaden your search for "Factor XII Light Chain" by refining your antibody search criteria in the Antibody Search box below. | | | Reactivity : This antibody reacts with the light chain of human Factor XII. | | | Your search for "Factor XII Light Chain" antibody returned 4 antibodies. |
|
http://www.biocompare.com/matrixsc/3194/2/6/8097/Factor+XII+Light+Chain.html
|
|
| |
| | Activated Factor XII (FXIIa) ELISA |
| | There are no related web resources associated with this product. | | | The FXIIa ELISA measures plasma levels of activated factor twelve by incorporating a monoclonal antibody which has been shown to have a high affinity for FXIIa but no detectable reaction with FXII or FXIIa inhibitor complexes. | | | The assay can be used to measure a key activation protein of the contact, or surface, activation system. |
|
http://www.axis-shield.com/product/productdetail.cfm?itemcount=81
|
|
| |
| | Hemophilia: Factor XII Deficiency |
| | Recommendation for the Patient with Factor XII Deficiency | | | Download the entire document in PDF (208 K) Copyright © 2004 / Canadian Hemophilia Society / All rights reserved |
|
http://www.hemophilia.ca/en/2.3.8.php
|
|
| |
| | cclement5 |
| | WINDOTTER : analysis of factor XI and factor XII. | | | CATH classification of thrombin and other coagulation factors. | | | Cn3D presentation of thrombin, factors VII, X and IX. |
|
http://www.geocities.com/cclement_us/outline7.html
|
|
|
